HRTX Stock Overview
A commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Heron Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.12 |
| 52 Week High | US$3.93 |
| 52 Week Low | US$1.04 |
| Beta | 1.81 |
| 11 Month Change | -38.12% |
| 3 Month Change | -40.11% |
| 1 Year Change | -18.25% |
| 33 Year Change | -88.54% |
| 5 Year Change | -95.61% |
| Change since IPO | -99.81% |
Recent News & Updates
Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge
Nov 13
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30%
Nov 13Recent updates
Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge
Nov 13Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30%
Nov 13Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%
Aug 08Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
May 30Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Apr 16Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results
Mar 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%
Dec 22Heron wins FDA nod for post-operative agent to address nausea and vomiting
Sep 16Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?
Aug 10Heron Therapeutics Q2 2022 Earnings Preview
Aug 08Heron Therapeutics proposes 34% cut in workforce as part of cost reduction plan
Jun 30Heron Therapeutics: Cash Is A Problem Again
Mar 31Heron Therapeutics: Changing Strategy After Disappointing Earnings
Mar 03Health Check: How Prudently Does Heron Therapeutics (NASDAQ:HRTX) Use Debt?
Jan 19Heron Therapeutics: Looking For Signs Of The Bottom
Oct 07Is Heron Therapeutics (NASDAQ:HRTX) Using Too Much Debt?
Oct 03Shareholder Returns
| HRTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.4% | -6.5% | -1.0% |
| 1Y | -18.2% | 14.6% | 30.3% |
Return vs Industry: HRTX underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: HRTX underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| HRTX volatility | |
|---|---|
| HRTX Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HRTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HRTX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 126 | Craig Collard | www.herontx.com |
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Heron Therapeutics, Inc. Fundamentals Summary
| HRTX fundamental statistics | |
|---|---|
| Market cap | US$180.99m |
| Earnings (TTM) | -US$27.97m |
| Revenue (TTM) | US$137.74m |
1.2x
P/S Ratio-6.1x
P/E RatioIs HRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HRTX income statement (TTM) | |
|---|---|
| Revenue | US$137.74m |
| Cost of Revenue | US$72.38m |
| Gross Profit | US$65.36m |
| Other Expenses | US$93.33m |
| Earnings | -US$27.97m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 47.45% |
| Net Profit Margin | -20.30% |
| Debt/Equity Ratio | -436.1% |
How did HRTX perform over the long term?
See historical performance and comparison